Abstract
The application of ATP-loaded liposomes has been shown effective against ischemic damage in several tissues. In this study, we have prepared ATP-containing liposomes capable of specific recognition of component (myosin) specific for ischemic myocardium. ATP-containing immunoliposomes specific towards cardiac myosin were obtained by the attachment of the monoclonal anti-cardiac myosin 2G4 antibody to the surface of ATP-containing PEGylated liposomes prepared by the freezing-thawing method. Since intracellular myosin is exposed only in the areas containing ischemically compromised cells with damaged plasmic membranes, such liposomes are expected to target these areas both in vitro and in vivo. The attachment of the antibody did not provoke their ATP release from the liposomes and only minimally influenced liposome size and size distribution. Liposome-attached anti-myosin 2G4 antibody preserved its specific activity; and anti-myosin antibody-bearing, ATP-loaded liposomes bound efficiently to the monolayer of myosin in ELISA. The preparation of myosin-specific ATP-loaded immunoliposomes represented an important step in the development of targeted delivery systems capable of providing energy support to ischemic myocardium in vivo.
Keywords: atp, liposomes, anti-myosin antibody, immunotargeting, elisa
Current Drug Delivery
Title: ATP-Containing Immunoliposomes Specific for Cardiac Myosin
Volume: 1 Issue: 1
Author(s): Wei Liang, Tatyana Levchenko, Ban-An Khaw and Vladimir Torchilin
Affiliation:
Keywords: atp, liposomes, anti-myosin antibody, immunotargeting, elisa
Abstract: The application of ATP-loaded liposomes has been shown effective against ischemic damage in several tissues. In this study, we have prepared ATP-containing liposomes capable of specific recognition of component (myosin) specific for ischemic myocardium. ATP-containing immunoliposomes specific towards cardiac myosin were obtained by the attachment of the monoclonal anti-cardiac myosin 2G4 antibody to the surface of ATP-containing PEGylated liposomes prepared by the freezing-thawing method. Since intracellular myosin is exposed only in the areas containing ischemically compromised cells with damaged plasmic membranes, such liposomes are expected to target these areas both in vitro and in vivo. The attachment of the antibody did not provoke their ATP release from the liposomes and only minimally influenced liposome size and size distribution. Liposome-attached anti-myosin 2G4 antibody preserved its specific activity; and anti-myosin antibody-bearing, ATP-loaded liposomes bound efficiently to the monolayer of myosin in ELISA. The preparation of myosin-specific ATP-loaded immunoliposomes represented an important step in the development of targeted delivery systems capable of providing energy support to ischemic myocardium in vivo.
Export Options
About this article
Cite this article as:
Liang Wei, Levchenko Tatyana, Khaw Ban-An and Torchilin Vladimir, ATP-Containing Immunoliposomes Specific for Cardiac Myosin, Current Drug Delivery 2004; 1 (1) . https://dx.doi.org/10.2174/1567201043480063
DOI https://dx.doi.org/10.2174/1567201043480063 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Patents on Cardiovascular Stem Cells
Recent Patents on Cardiovascular Drug Discovery Harvesting New Therapeutic Avenues with Stem Cell Applications
Current Neurovascular Research Myocardial Protection Against Ischemia-Reperfusion Injury: Novel Approaches in Maintaining Homeostatic Stability in Blood
Recent Patents on Cardiovascular Drug Discovery The Challenges of Blood Pressure Control in Dialysis Patients
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Pre-procedural Elevated White Blood Cell Count and Neutrophil-Lymphocyte (N/L) Ratio are Predictors of Ventricular Arrhythmias During Percutaneous Coronary Intervention
Cardiovascular & Hematological Disorders-Drug Targets Modulation of Inflammatory Response Improves Myocardial Infarct Healing in Rats
Current Pharmaceutical Design Hyperhomocysteinemia and Sudden Cardiac Death: Potential Arrhythmogenic Mechanisms
Current Vascular Pharmacology Matrix Metalloproteinase Knockout Studies and the Potential Use of Matrix Metalloproteinase Inhibitors in the Rheumatic Diseases
Current Drug Targets - Inflammation & Allergy Stem Cells and Cardiac Disease: Where are We Going?
Current Stem Cell Research & Therapy Regulation of Angiogenesis by Macrophages, Dendritic Cells, and Circulating Myelomonocytic Cells
Current Pharmaceutical Design Structure and Function of Poly(ADP-ribose) Polymerase-1: Role in Oxidative Stress-Related Pathologies
Current Vascular Pharmacology The Role of Vascular Cell Senescence in Atherosclerosis: Antisenescence as a Novel Therapeutic Strategy for Vascular Aging
Current Vascular Pharmacology Triple Threat: The Na+/Ca2+ Exchanger in the Pathophysiology of Cardiac Arrhythmia, Ischemia and Heart Failure
Current Drug Targets Occurrence and Clinical Impact of Microembolic Signals (MES) in Patients with Chronic Cardiac Diseases and Atheroaortic Plaques - A Systematic Review
Current Vascular Pharmacology From Bone to Brain: Human Skeletal Stem Cell Therapy for Stroke
Central Nervous System Agents in Medicinal Chemistry PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention
Current Medicinal Chemistry Radiopharmaceuticals for Oncology Drug Development: A Pharmaceutical Industry Perspective
Current Pharmaceutical Design Pathophysiology, Diagnosis and Clinical Management of Hepatorenal Syndrome: From Classic to New Drugs
Current Vascular Pharmacology The Cardiologist in the Periphery: Indications and Usefulness of Peripheral Artery Invasive Angiography in Patients Undergoing Coronary Angiography
Current Medical Imaging Should We be Concerned About the Inflammatory Response to Endovascular Procedures?
Current Vascular Pharmacology